01169BCB-82ED-4492-9FD0-630CCEA70023
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.341655716162943
- age_years
- 28
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.514
- NOTCH_SIGNALING+0.511
- PROTEIN_SECRETION+0.511
- TGF_BETA_SIGNALING+0.511
- E2F_TARGETS+0.470
- MITOTIC_SPINDLE+0.463
- ANGIOGENESIS+0.456
- MYC_TARGETS_V2+0.421
- MYC_TARGETS_V1+0.403
- IL6_JAK_STAT3_SIGNALING+0.391
Top 10 suppressed
- KRAS_SIGNALING_DN-0.414
- PANCREAS_BETA_CELLS-0.250
- SPERMATOGENESIS-0.230
- MYOGENESIS-0.133
- APICAL_SURFACE-0.078
- ESTROGEN_RESPONSE_LATE-0.041
- BILE_ACID_METABOLISM-0.007
- OXIDATIVE_PHOSPHORYLATION+0.021
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.031
- COAGULATION+0.049
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.954 |
| 2 | SRR934840 | — | — | 0.948 |
| 3 | E6AA40DA-9AB7-478B-B46B-827F9AFE52D1 | — | — | 0.947 |
| 4 | 1A9B5D3A-CEB0-4225-9C3D-CBE98A007A3A | — | — | 0.943 |
| 5 | F8F6611A-A71A-4847-92B2-15723B9ED0B8 | — | — | 0.940 |
| 6 | SRR934860 | — | — | 0.938 |
| 7 | D5191F3D-028E-401C-927E-483F6884BE39 | — | — | 0.937 |
| 8 | SRR934907 | — | — | 0.935 |
| 9 | SRR934861 | — | — | 0.933 |
| 10 | SRR934827 | — | — | 0.933 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.514 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.511 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.511 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.511 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.463 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.456 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.421 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.403 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.391 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.369 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.364 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.359 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.338 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.337 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.329 | Inavolisib | — uncovered |
| COMPLEMENT | 0.327 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.318 | Idelalisib | — uncovered |